Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

▤ Summary

Rocket Pharmaceuticals closed the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million. The company received the voucher after FDA approval of KRESLADI, its gene therapy for severe leukocyte adhesion deficiency-I. The transaction adds non-dilutive capital and lifts Rocket’s pro forma cash position to about $322.6 million. Rocket says the proceeds should fund operations into the second quarter of 2028 and support its gene therapy pipeline.

▦ Linked Companies